Johnson & Johnson's Q1 2019 earnings call showed a positive outlook, with management highlighting strong performance in pharmaceuticals, particularly in oncology and immunology.  The call also featured a slight increase in guidance, reflecting confidence in the company's ability to continue strong growth while navigating a challenging market landscape.  Management's tone emphasizes continued focus on long-term strategies, new product launches,  and cost-cutting initiatives.
[1]
